Please login to the form below

Not currently logged in
Email:
Password:

Gilead and Verily team up to map inflammatory diseases

Computational analysis could provide deeper understanding of disease

Gilead

Gilead’s recent focus has been on expanding into cell and gene therapy, but it also has ambitions to be a player in the huge inflammatory disease markets of rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.

Today it announced a deal with Google’s life science and healthcare division Verily to identify and better understand the immunological basis of these three common and serious inflammatory diseases.

Lupus in particular is currently without treatment that can adequately control the disease, and Gilead has its candidate filgotinib (co-developed with Galapagos) in phase II.

The partnership will be the first large-scale deployment of Immunoscape, Verily’s platform for generating immunological data and insights. As such, the three-year deal could be a breakthrough for the health tech firm, which has promised much since it was launched in late 2015, but has yet to produce evidence of its ‘disruptive’ potential.

Gilead is understood to be paying Verily $90m to undertake the work - a sum it hopes it can recoup in greater long-term R&D productivity.

The Immunoscape platform combines immunogenomic phenotyping and advanced computational analysis techniques to profile the molecular characteristics of inflammatory diseases at high resolution. Gilead will provide clinical data and thousands of immune cell samples from participants before, during and after administration of novel drugs in the company’s ongoing phase II and phase III clinical studies.

“Inflammatory diseases are complex and heterogeneous, and despite treatment advances, most patients experience neither deep nor long-lasting remissions,” said John McHutchison, MD, Chief Scientific Officer, Head of Research and Development, Gilead. “We are excited to be collaborating with the scientists at Verily to accelerate our understanding of these common and serious inflammatory diseases. We hope to ultimately improve patient outcomes using this cutting-edge technology to identify molecular disease pathways that would otherwise remain undetected.”

“With the Immunoscape platform, we are seeking to develop a molecular map of inflammatory diseases that will help us identify and characterise disease mechanisms,” added Jessica Mega, MD, Chief Medical Officer at Verily. “This collaboration with Gilead is an incredible opportunity to learn much more about these immune-mediated conditions than ever before, and to hone in on potential paths to deliver more precise medicine to patients.”

All data and samples will be coded to protect patient privacy, and any findings of the analysis will include patient data only in aggregate.

The alliance with Gilead adds to Verily’s joint ventures with GSK, Galvani Bioelectronics and with Sanofi’s diabetes management platform Onduo.

Article by
Andrew McConaghie

1st May 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics